# Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

Source: https://onco.cc/trials/nct07217119/  
OnCo record `nct07217119` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Belantamab mafodotin in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.

## Summary

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM is a phase 1/2 interventional study registered as NCT07217119 by GlaxoSmithKline, with 25 participants enrolled, started 2019-11-26 and due to reach its primary completion in 2025-04-17. Interventions recorded: Belantamab mafodotin, Feladilimab. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: ctgov-ingest
- Registry id: NCT07217119
- Phase: 1/2
- Setting: A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 2 - Belantamab Mafodotin and Feladilimab (GSK3359609) in Combination
- Sponsor: GlaxoSmithKline
- Enrolled: 25
- Outcomes: Dose Expansion (DE) Phase: Number of Participants With Dose Limiting Toxicities (DLTs): 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 participants vs 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 participants vs 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0 participants; DE Phase: Overall Response Rate (ORR): 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 44% vs 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 50% vs 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 67%

## Sources

- ClinicalTrials.gov NCT07217119: https://clinicaltrials.gov/study/NCT07217119

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Belantamab mafodotin](https://onco.cc/drugs/belantamab-mafodotin/), [Feladilimab](https://onco.cc/drugs/feladilimab/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct07217119.json